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1282HLA-DPB1 Mismatching Results in the Generation
of a Full Repertoire of HLA-DPB1-Specific CD41
T Cell Responses Showing Immunogenicity
of all HLA-DPB1 Alleles
Caroline E. Rutten,1 Simone A. P. van Luxemburg-Heijs,1 Edith D. van der Meijden,1
Marieke Griffioen,1 Machteld Oudshoorn,2,3 Roel Willemze,1 J. H. Frederik Falkenburg1Clinical studies have indicated that HLA-DPB1 functions as a classical transplantation antigen in allogeneic stem
cell transplantation. Mismatching for HLA-DPB1 was associated with an increased risk of graft-versus-host
disease (GVHD), but also a decreased risk of disease relapse. However, specific HLA-DPB1 mismatches
were associated with poor clinical outcome. It was suggested that this unfavorable effect was caused by a dif-
ference in immunogenicity between HLA-DPB1 alleles. To analyze whether immunogenicity of HLA-DPB1
mismatches could be predicted based on the presence or absence of specific amino acid sequences we devel-
oped a model to generate allo-HLA-DPB1 responses in vitro. We tested in total 48 different stimulator/re-
sponder combinations by stimulating CD41 T cells from 5 HLA-DPB1 homozygous individuals with the
same antigen-presenting cells transduced with different allo-HLA-DPB1 molecules. HLA-DPB1 molecules
used for stimulation comprised 76% to 99% of HLA-DPB1 molecules present in different ethnic populations.
We show that all HLA-DPB1 mismatches as defined by allele typing resulted in high-frequency immune re-
sponses. Furthermore, we show that crossrecognition of differentHLA-DPB1molecules is a broadly observed
phenomenon.We confirm previously described patterns in crossrecognition, and demonstrate that a high de-
gree in similarity betweenHLA-DPB1molecules is predictive for crossrecognition, but not for immunogenicity.
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Allogeneic hematopoietic stem cell transplantation
(allo-SCT) is anestablished treatment for a variety of he-
matologic malignancies [1]. A significant part of the
therapeutic effect of allo-SCT can be attributed to
donor-derived T cells recognizing antigens on residual
malignant cells, thereby inducing a graft-versus-
leukemia (GVL) effect [2]. When such antigens are not
only present on hematopoietic cells but also on non-
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[3,4]. Because allo-reactive T cells recognizing HLA-
mismatched alleles are present in high frequencies in
peripheral blood (PB) [5], HLA-mismatched SCT may
result in strong allo-immunity. To reduce the risk of
GVHD and allograft rejection, patient and donor are
preferably matched for the HLA-class-I molecules
HLA-A, -B, -C, and the HLA-class-II molecules
HLA-DRB1 and HLA-DQB1 (10/10 match) [6-8].
However, a perfectly matched donor is not always
available. Several studies have demonstrated the im-
portance of functional matching to select the best
available donor. It has been suggested that mismatches
at some loci may be better tolerated than others [9-11].
Minimal mismatches resulting in single amino acid
substitutions have been associated with a significant
increased risk of GVHD and treatment-related mor-
tality (TRM) [12,13]. In contrast, highly diverged
HLA-class-I mismatches with more than 5 amino
acid substitutions in both the a-helix and b-sheet of
an HLA-class-I molecule in combination with a nega-
tive cytotoxic T-lymphocyte precursor test have been
shown to be better tolerated than less diverged mis-
matches [14]. These studies indicated that the number
Biol Blood Marrow Transplant 16:1282-1292, 2010 1283Immunogenicity of HLA-DPB1of amino acid substitutions between mismatched
HLA-alleles was not predictable for the outcome of al-
loreactivity.
HLA-DPB1 is often not taken into consideration
in donor selection. Recent large clinical studies
showed that HLA-DPB1 did function as a classical
transplantation antigen because HLA-DPB1 mis-
matching was associated with both GVHD and GVL
reactivity [6,15]. The overall mortality of patients
who received an HLA-DPB1 matched or mismatched
SCT did not statistically differ, possibly because of
a balanced effect of increased GVHD and reduced re-
lapse rate. Remarkably, specific HLA-DPB1 mis-
matches have been associated with poor clinical
outcome [16-21]. It was suggested that matching at
an epitope level may be clinically more relevant in
terms of transplant outcome than matching at an
allele level. An algorithm was developed in which
permissive and non-permissive mismatches were
defined [19]. HLA-DPB1 molecules were classified
in 3 different immunogenicity groups according to
their recognition by HLA-DPB1*09-specific CD41
T cell clones. Recently, the classification was modified
introducing a fourth category in the algorithm [21].
Individuals were not supposed to elicit strong anti-
HLA-DP responses to HLA-DPB1 molecules classi-
fied within the same immunogenicity group, based
on the hypothesis that T cells should not respond to
foreign HLA-DPB1 molecules sharing specific amino
acids with the ‘‘self’’-HLA-DPB1 allele. These mis-
matches were assigned to be permissive mismatches.
In contrast, strong T cell responses were expected
only to be generated against HLA-DPB1 molecules
classified in higher immunogenic groups representing
non-permissive mismatches [19].
Recently, we demonstrated the in vivo occurrence
of polyclonal HLA-DPB1-specific immune responses
following both permissive and non-permissive
HLA-DPB1 mismatched stem cell transplantation
and donor lymphocyte infusion (DLI) [22]. In the
present study we tested these CD41Tcells with differ-
ent HLA-DPB1 specificity for crossrecognition of
other HLA-DPB1 molecules and confirmed previ-
ously described patterns in crossrecognition [19,20].
In addition, crossrecognition of other HLA-DPB1
molecules was found, which did not correspond to
the previously proposed algorithm. To analyze
whether immunogenicity of HLA-DPB1 mismatches
could be predicted based on the presence or absence
of specific amino acid sequences in the HLA-DPB1
molecule, we developed a model to generate allo-
HLA-DP responses in vitro. Using this model, we
tested 48 different combinations. Responders were se-
lected by homozygous expression of 1 of the 4 most
commonHLA-DPB1 alleles in the northern European
population. HLA-DPB1 molecules used for stimula-
tion comprised 76% to 99% of the HLA-DPB1 allelespresent in different ethnic populations [15,23]. We
show that all HLA-DPB1 mismatches as defined by
allele typing resulted in high-frequency immune
responses, and also between individuals expressing
HLA-DPB1 molecules that were frequently crossre-
cognized. Together, these data demonstrate that
a high degree of similarity in amino acid sequence
betweenHLA-DPB1molecules is predictive for cross-
recognition but not for immunogenicity, and illustrate
that T cell recognition patterns may not predict
alloreactivity.MATERIALS AND METHODS
Cell Collection and Preparation
PB samples were obtained from healthy donors
after approval by the LUMC institutional review board
and informed consent according to the Declaration of
Helsinki. Mononuclear cells (MNC) were isolated by
Ficoll-Isopaque separation and cryopreserved. Stable
Epstein-Barr virus (EBV)-transformed B cell lines
(EBV-LCL) were generated using standard proce-
dures. EBV-LCL and HeLa cells were cultured in
Iscove’s modified Dulbecco’s medium (IMDM,
BioWhittaker, Verviers, Belgium) supplemented with
10% bovine fetal serum (FBS, BioWhittaker).
Flow cytometry
The monoclonal antibodies (mAbs) anti-CD4
fluorescein isothiocyanate (FITC), anti-CD14 phyco-
erythrin (PE), anti-Nerve Growth Factor Receptor
(NGFR)-PE, anti-CD3 Peridinin Chlorophyll Pro-
tein (PerCP), anti-CD19 allophycocyanin (APC), and
anti-interferon-g (IFN-g)-APC were obtained from
Becton Dickinson (BD, San Jose, CA, USA). Anti-
CD56-APC and anti-CD154-PE were obtained from
Beckman Coulter (Fullerton, CA, USA). Anti-CD8-
APC mAbs ware purchased from Caltag Laboratories
(Burlingame, CA, USA) and anti-HLA-DP-PE mAbs
were obtained from Leinco Technologies (St. Louis,
MO, USA). Flow cytometric analysis was performed
on a BD flow cytometer using CellquestPro software,
and cell sorting was performed using a BD FACSAria
cell-sorting system.
Transduction of HeLa Cells with Different
Retroviral Constructs
HLA-class-II negativeHeLa cells were retrovirally
transduced with 12 different combinations of
HLA-DPB1 and HLA-DPA1 molecules as described
in Table 1. To allow appropriate costimulation and
processing of the HLA-DP molecules, HeLa cells
were first transduced with CD80, Invariant chain (Ii),
and HLA-DM. HLA-DMA, HLA-DMB, and
CD80-Ii were cloned into separate pLZRS retroviral
Table 1. HLA-DP Constructs Used for Transduction
Construct1
HLA-DPB1* HLA-DPB1* HLA-DPA1*
Frequency2
(%)
Classification3
(Group)
0101 0101 0201 3.6 4
0201 0201 0103 10.9 3
0301 0301 0103 12.6 2
0401 0401 0103 40.9 4
0402 0402 0103 13 4
0501 0501 0202 3.2 4
0601 0601 0103 2.4 4
0901 0901 0201 1.2 1
1101 1101 0201 2.4 4
1301 1301 0201 1.2 4
1401 1401 0201 1.6 2
1701 1701 0201 2.4 1
1Construct names for combination of HLA-DPB1 and HLA-DPA1 mol-
ecules used for transduction into HeLa-II cells or EBV-LCL.
2Frequencies of HLA-DPB1 molecule in northern European population
according to Begovich et al. [23].
3HLA-DPB1 molecules were previously classified in 4 immunogenicity
groups: highly immunogenic (group 1), intermediate immunogenic
(groups 2 and 3), or low immunogenic (group 4) [21].
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gene DNGF-R and HLA-DMB with enhanced green
fluorescence protein (eGFP). HLA-DPA1 and
HLA-DPB1 molecules were cloned into separate
MP71-IRES retroviral vectors containing the marker
genes eGFP or DNGF-R, respectively. The identity
of all constructs was verified by sequencing. Retroviral
supernatants were generated using packagingF-NX-A
cells as previously described [24,25] and used for
transduction of HeLa cells or EBV-LCL using
recombinant human fibronectin fragments CH-296
(BioWhittaker) [25,26].
HLA-DM and CD80-Ii-transduced HeLa (He-
La-II) cells were purified by flow cytometric cell sorting
based on expression of both marker genes and CD80
staining. Selected cells were subsequently transduced
with HLA-DPA1 and HLA-DPB1 constructs. HLA-
DP-transduced HeLa-II cells were selected based on
positive staining for anti-HLA-DP-PE. EBV-LCL
expressing the specifically transduced HLA-DPA1
and HLA-DPB1 molecules were isolated by selecting
for eGFP and DNGF-R double-positive cells.Characterization of CD41 T Cell Clones
To analyze crossrecognition of different
HLA-DPB1 molecules by our previously isolated
HLA-DPB1-specific CD41 T cell clones [22], IFN-g
production in response to HeLa-II cell lines trans-
duced with different HLA-DPB1 molecules and
HLA-DP-negative HeLa-II cells was determined. To
determine IFN-g production, 5000T cells were cocul-
tured with 0.03*106 stimulator cells in culture medium
consisting of IMDM supplemented with 5% human
serum and 5% FBS supplemented with 10 IU
interleukin-2 per mL (IL-2, Chiron, Amsterdam, The
Netherlands). After overnight incubation, superna-
tants were harvested, and IFN-g production wasmeasured by enzyme-linked immunosorbent assay
(ELISA; Centraal Laboratorium voor Bloedtransfusie-
dienst, CLB, Amsterdam, The Netherlands).
To identify HLA-DPB1-specific CD41 T cell
clones with the same specificity but derived from dif-
ferent clonal origin, T cell receptor (TCR)-Vb-chain
analysis was performed by flow cytometric analysis.
CD41 T cell clones were stained with specific
antibodies for different TCR-Vb chains using
a TCR-Vb repertoire kit (Beckman Coulter) and
analyzed by flow cytometry.Generation of HLA-DPB1-Specific CD41 T Cell
Lines
To study immunogenicity ofHLA-DPB1 in differ-
ent stimulator/responder combinations we developed
a model to generate allo-HLA-DPB1 responses in vi-
tro. Twelve different HLA-DPB1-transduced HeLa-
II cell lines were used to stimulate purified CD41 T
cells derived from different HLA-DPB1 homozygous
responders. Responder cells were HLA-DPB1*0201,
*0301, *0401, and *0402. CD41T cells were first puri-
fied from PB-MNC using magnetic untouched CD41
T cell isolation beads (Miltenyi Biotec, GmbH, Ber-
gisch Gladbach, Germany) according to the manufac-
turer’s instructions. Next, negative fractions were
stained with anti-CD4-FITC, anti-CD14-PE, and
anti-CD8-APC, anti-CD56-APC, and anti-CD19-
APC. CD41, CD142/CD82/CD562/CD192 cells
were selected using flow-cytometric cell sorting. 1 
106 purified CD41 T cells were stimulated with 0.1 
106 irradiated (30 Gy) HLA-DP-transduced HeLa-II
cells in culture medium supplemented with 50 IU IL-
2/mL. At day 14, CD41 T cell lines were analyzed
for specific recognition of various cell lines.Characterization of CD41 T Cell Lines
To analyze specificity of the CD41 T cell lines
stimulated with different HLA-DPB1 molecules,
IFN-g production in response to HeLa-II cells trans-
duced with 12 different HLA-DPB1 alleles (including
the autologous control) andHLA-DP-negative HeLa-
II cells was determined. To further confirm specificity
for allo-HLA-DPB1, IFN-g production in response to
autologous responder EBV-LCL transduced with the
relevant HLA-DPB1 molecules used for stimulation
was determined. IFN-g production was determined
in harvested supernatants or by intracellular cytokine
staining.
To determine IFN-g release in supernatants,
25,000, 10,000, or 2000 CD41T cells were cocultured
with 0.05  106 stimulator cells in a final volume of
150-mL culture medium. Supernatants were harvested
following overnight incubation, and IFN-g produc-
tion was measured by ELISA.
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T cells were restimulated with 0.05  106 stimulator
cells in culture medium supplemented with 10 mg/
mL Brefeldin-A (Sigma-Aldrich, St. Louis, MO,
USA). After 4 hours incubation, CD41 T cells were
surface stained with CD4-FITC and CD3-PerCP-
labeledMAbs. Cells were washed, fixed, and permeabi-
lized using 0.1% Saponin (Sigma-Aldrich) for 20 min-
utes at 4C. Next, cells were stained intracellularly
with CD154-PE and IFN-g-APC-labeled MAbs, and
analyzed by flow cytometry.Generation of HLA-DPB1-Specific CD41 T Cell
Clones
To analyze the diversity of HLA-DPB1*1401-
specific CD41 T cell responses, HLA-DPB1*14-
specific CD41 T cells were clonally isolated from
a T cell line generated as described earlier. At day
14 restimulation was performed, and after 4 hours
of incubation, activated IFN-g producing CD41 T
cells were stained using the IFN-g capture assay
(Miltenyi Biotec GmbH) according to the manufac-
turer’s instructions. PE labeled IFN-g producing
CD41 T cells were stained with anti-CD4-APC
conjugated mAbs and counterstained with propi-
dium iodide (PI, Sigma) immediately prior to cell
sorting to exclude dead cells. Viable (PI-negative),
CD4-positive IFN-g secreting lymphocytes were
sorted single cell per well into U-bottom microtiter
plates containing 100-mL feeder mixture consisting
of culture medium supplemented with IL-2 (120
IU/mL), phytohemagglutinin (PHA, 0.8 mg/mL,
Murex Biotec Limited, Dartford, UK), and 50
Gy-irradiated allogeneic third-party PB-MNC
(0.05  106/mL). Proliferating T cell clones were
selected and further expanded using nonspecific
stimulation and third-party feeder cells.RESULTS
HLA-DPB1-Transduced HeLa-II Cells
as Antigen-Presenting Cells (APCs)
To study recognition of HLA-DPB1 molecules we
used HLA-class II-negative HeLa cells transduced
with different HLA-DP molecules as APCs. By using
the sameAPCs inall experiments, the variabilitybetween
different stimulations was limited to the expression of
different HLA-DPB1 molecules. Because HeLa cells
do not endogenously express HLA-class-II molecules,
we first transduced CD80, Ii, and HLA-DM into the
HeLacells (HeLa-II) to allow appropriate costimulation
andprocessingof transducedHLA-DPmolecules.Next,
HeLa-II cells were transduced with different
combinations of HLA-DPA1 and HLA-DPB1 mole-
cules. HLA-DPB1 molecules were cotransduced withHLA-DPA1 molecules found in positive linkage
disequilibrium in different populations [23] (Table 1).
Crossrecognition of HLA-DPB1 Molecules by
Different HLA-DPB1-Specific CD41 T Cell
Clones
To analyze whether CD41 T cell clones with dif-
ferent HLA-DPB1 specificities showed similar cross-
recognition patterns as previous demonstrated [19,20]
we tested HLA-DPB1*0201, *0301, or *0401-specific
CD41 T cell clones expressing different TCR-Vb for
recognition of 12 different HLA-DPB1 molecules.
HLA-DPB1-specific CD41 T cells have previously
been isolated from 2 patients during clinical immune
responses following HLA-DPB1 mismatched SCT
and DLI [22]. In Figure 1, crossrecognition patterns
of the different CD41 T cell clones is shown. Individ-
ualCD41Tcell clones directed against the sameHLA-
DPB1 allele exhibited different patterns in crossrecog-
nition demonstrating that theCD41Tcell clones were
specific for different epitopes. Interestingly, in accor-
dance to previous reports [19,27,28], most HLA-
DPB1*03-specific CD41 T cell clones showed
crossrecognition of HLA-DPB1*1401, illustrating
the similarity of these 2 HLA-DPB1 molecules. In ad-
dition,HLA-DPB1*0201- andHLA-DPB1*0301-spe-
cific CD41 T cell clones showed crossrecognition of
other HLA-DPB1 molecules, which did not corre-
spond to the previously proposed algorithm [19,21].
Generation of HLA-DPB1-Specific CD41 T Cell
Responses In Vitro
To analyze whether frequently observed crossreac-
tivity between specific HLA-DPB1 molecules influ-
enced mutual immunogenicity, we developed
a model to generate allo-HLA-DPB1 responses in vi-
tro. In this model we stimulated purified CD41T cells
form healthy individuals with HeLa-II cells trans-
duced with different HLA-DPB1 molecules and ana-
lyzed their specificity at day 14 after stimulation.
First, we analyzed the capacity of HLA-DPB1-
transduced HeLa-II cells to induce HLA-DPB1-
specific CD41 T cell responses in vitro. We purified
CD41 T cells from a cryopreserved fraction of DLI
stored for 1 of the patients described before [22,29],
and stimulated these donor-derived CD41 T cells
with HLA-DPB1*03-transduced HeLa-II cells. Four-
teen days after stimulation CD41 T cells were tested
for specific recognition of the cell line used for stimu-
lation by intracellular IFN-g measurement as well as
IFN-g ELISA. Specific IFN-g production was ob-
served by 8% to 12% of CD41 T cells in response to
restimulation with HLA-DPB1*03-transduced
HeLa-II cells and not in response to HeLa-II cells
transduced with control HLA-DPB1 molecules or
HLA-DP-negative HeLa-II cells, illustrating a high
24-a 20 - 337 - - 726 - - - - - - -
24-b 7.1 - - - - 764 - - - - - - -
24-c 12 - - - - 632 - - - - - - -
24-d 9 - 346 - - 834 - - - - - - -
24-e ? - - - - 733 - - - - - - -
--------500867--925-e
25-a 13.1 - - 930 446 - - - - - - - -
25-b 12 - - 871 - - - - - - - - -
25-c 17 - - 869 - - 163 - - - - 437 -
25-d 7.1 - - 950 840 - - - - - 914 919 -
25-f ? - - 857 610 - - - - - - - -
A
HLA-DPB1*0201
Specific CD4+ 
T cell clones
B
HLA-DPB1*0301
Specific CD4+ 
T cell clones
C
HLA-DPB1*0401
Specific CD4+ 
T cell clones
28-a 12 - - - - - - 437 - - - - -
28-b 17 - - - - - 181 651 - - - - -
28-c 13.2 - - - - - - 484 - - - - -
28-d 21.3 - - - - - 868 679 - - - - -
28-e ? - - - - - - 915 633 - - - 749
Clone  TCR-V
4 puorG3 puorG2 puorG1 puorG
0901 1701 0301 1401 0201 0101 0401 0402 0501 0601 1101 1301
Figure 1. Differential crossrecognition of HLA-DPB1 molecules by CD41 T cell clones with the same HLA-DPB1 specificity. Different HLA-
DPB1*0201 (n5 5), *0301 (n5 6), or *0401 (n5 5)-specific CD41 T cell clones, identified by different TCR-Vb expression, were tested for recognition
of 12 different HLA-DPB1 transduced HeLa-II cell lines. Each row represents recognition of the 12 different HLA-DPB1 molecules by 1 CD41 T cell
clone. Overnight IFN-g production measured in 50 mL supernatant is shown (pg/mL). ‘‘- ‘‘ indicates\100 pg/mL IFN-gmeasured. (A) HLA-DPB1*0201-
specific CD41 T cell clones were isolated during clinical immune response to DLI from an HLA-DPB1*0402, 0501 typed donor. (B) HLA-DPB1*0301-
specific CD41 T cell clones isolated clinical immune response to DLI from an HLA-DPB1*0402, 0501 typed donor. (C) HLA-DPB1*0401-specific CD41
T cell clones isolated during the clinical immune response to DLI from an HLA-DPB1*0301, 0402 typed donor.
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not shown). Similarly, in IFN-g ELISA specific recog-
nition of HLA-DPB1*03-transduced HeLa-II cells
and not HeLa-II cells transduced with control HLA-
DPB1 molecules or HLA-DP negative HeLa-II cells
was shown. Specificity for allo-HLA-DPB1*03 of the
CD41 T cell line was further confirmed by specific
recognition of HLA-DPB1*03-transduced autologous
responder EBV-LCL (Figure 2A).
To confirm specific recognition of HLA-
DPB1*03-transduced HeLa-II cells and HLA-
DPB1*03-transduced responder EBV-LCL by a single
CD41 T cell, HLA-DPB1*03-specific CD41 T cells
were clonally isolated from this CD41T cell line using
the IFN-g capture assay. In total, 24 CD41 T cell
clones using at least 8 different TCR-Vb chains were
expanded and tested for specific recognition of HLA-
DPB1*03 (Figure 2B). The data showed that 19
CD41 T cell clones specifically recognized both
HLA-DPB1*03-transduced HeLa-II cells and HLA-
DPB1*03-transduced autologous responder EBV-
LCL. Five CD41 T cell clones only recognized
HLA-DPB1*03-transduced HeLa-II cells, probably
representing recognition of polymorphic peptides or
monomorphic cell type-specific peptides presented in
the transduced HLA-DP molecules. These results
showed that HeLa-II cells transduced with HLA-DP
molecules can be used as stimulator cells for in vitroinduction of polyclonal HLA-DPB1-specific CD41
T cell responses.Strong and Diverse HLA-DPB1-Specific
Immune Responses Were Generated Between
Individuals Expressing Frequently
Crossrecognized HLA-DPB1 Alleles
To analyze whether frequently observed crossreac-
tivity between HLA-DPB1*0301 and HLA-DPB1
*1401 resulted in lowmutual immunogenicitywe gener-
ated an HLA-DPB1*1401-specific immune response
from an HLA-DPB1*0301 typed responder using
our model. We generated HLA-DPB1*1701-, HLA-
DPB1*0201-, and HLA-DPB1*0401-specific immune
response from the same individual as a comparison.
HLA-DPB1moleculeswere selectedbasedon their clas-
sification in different immunogenicity groups [21]. Puri-
fied CD41 T cells were stimulated with HeLa-II cells
transduced with the 1 of these 4 different HLA-DPB1
molecules. Fourteen days after stimulation CD41 T
cells were tested for specific recognition of the relevant
HLA-DPB1molecules used for stimulation.The gener-
ation of these 4HLA-DPB1-specific immune responses
was demonstrated by specific IFN-g production in re-
sponse to restimulation with the HLA-DPB1 molecule
used for stimulation and not in response to responder
HLA-DPB1 molecules (Figure 3A). Specificity for
IFN-γ (pg/ml)
A
HeLa-II
HeLa-II + DPB1*03
HeLa-II + DPB1*02
Responder EBV-LCL
Responder + DPB1*03
Responder + DPB1*02
T-cells
0 200 400 600 800 1000 1200 1400
0 100 200 300 400 500 600
B
IFN-γ (pg/ml)
5 clones
19 clonesHeLa-II
HeLa-II + DPB1*02
HeLa-II + DPB1*03
Responder + DPB1*02
Responder + DPB1*03
T-cells
HeLa-II
HeLa-II + DPB1*02
HeLa-II + DPB1*03
Responder + DPB1*02
Responder + DPB1*03
T-cells
Figure 2. In vitro generation of an HLA-DPB1*03-specific CD41 T cell
line. (A) CD41 T cells purified from an HLA-DPB1*0402, 0501 typed
responder were stimulated with HeLa-II cells transduced with HLA-
DPB1*0301. At day 14, CD41 T cells were tested for recognition of
untransduced HeLa-II cells or responder EBV-LCL and HeLa-II cells or
responder EBV-LCL transduced with HLA-DPB1*03 or random control
HLA-DPB1*02. IFN-g release (pg/mL) in 50 mL supernatant is shown
after overnight incubation with different stimulator cells. (B) IFN-g pro-
duction from 24 HLA-DPB1*03-specific CD41 T cell clones in response
to different stimulators was determined in 50 mL supernatant. Recogni-
tion pattern shown in black bars was observed for 19 CD41 T cell
clones, whereas the recognition pattern shown by the white bars was
observed for 5 CD41 T cell clones.
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firmed by specific recognition of the autologous re-
sponder EBV-LCL, transduced with the relevant
HLA-DPB1 molecules used for stimulation (data not
shown).
To analyze whether there was a difference in fre-
quencies of HLA-DPB1-specific CD41T cells gener-
ated against the different HLA-DPB1 molecules, the
number of responder cells used for restimulation
were titrated in IFN-g ELISA (Figure 3B). All 4
HLA-DPB1-specific CD41T cell lines showed signif-
icant IFN-g release using 2000 responder cells dem-
onstrating a high frequency of HLA-DPB1-specific
CD41 T cells in all these cell lines.
To determine the diversity of this HLA-
DPB1*1401-specific immune response, CD41 T cells
were clonally isolated. Twelve HLA-DPB1*14-specific
CD41 T cell clones using 4 different TCR-Vb chains
were tested for crossreactive recognition of other
HLA-DPB1molecules. Only 1 HLA-DPB1*1401-spe-
cific CD41 T cell clone showed crossrecognition of
HLA-DPB1*0901, whereas 11 CD41 T cell clones
showed no crossrecognition of other HLA-DPB1
molecules (data not shown).Next, we analyzed whether the HLA-DPA1 mole-
cule contributed to the specificity of this allo-HLA-
DP response. We analyzed whether recognition of
allo-HLA-DPB1*14 depended on expression of the
HLA-DPA1*0201 molecule used for stimulation.
Seven CD41 T cell clones were tested for recognition
of HeLa cells tranduced with HLA-DPB1*1401/
DPA1*0201 and HeLa cells transduced with HLA-
DPB1*1401/HLA-DPA1*0103. Similar membrane
expression of the different HLA-DP constructs was
confirmed by flow cytometry (data not shown). For 4
CD41 T cell clones, recognition depended on the
presence of HLA-DPA1*0201 used for stimulation be-
cause no IFN-g production was observed in response
to HeLa cells transduced with HLA-DPB1*1401/
DPA1*0103 (Figure 3C). For 3 HLA-DPB1*14-spe-
cific CD41 T cell clones, recognition in response to
stimulationwithHeLa cells transducedwith a different
HLA-DPa chain was preserved. CD41 T cell clones
with the sameTCR-Vb as identified by antibody stain-
ing showed different recognition patterns, further
demonstrating the diversity of this immune response.
These data demonstrate that minor differences
between HLA-DPB1 molecules expressed by stimula-
tor and responder cells resulted in high-frequency
polyclonal CD41 T cell response.HLA-DPB1-Specific Immune Responses Were
Generated from all HLA-DPB1 Mismatch
Combinations
To determine immunogenicity of HLA-DPB1
molecules in multiple different stimulator/responder
combinations, CD41 T cells purified from 4 healthy
individuals were stimulated with HeLa-II cells trans-
duced with 11 different allo-HLA-DPB1 molecules.
Responders were selected based on homozygous
expression of HLA-DPB1*0201, *0301, *0401, or
*0402. In total, 44 different stimulator/responder
combinations were analyzed for the generation of
allo-HLA-DPB1-specific immune responses. At day
14 after stimulation, CD41T cells were tested for spe-
cific recognition of the relevantHLA-DPB1molecules
used for stimulation. HLA-DPB1-specific immune re-
sponseswere generated in 42of 44 stimulations as dem-
onstrated by specific IFN-g production in response to
restimulation with theHLA-DPB1-transducedHeLa-
II cell lines used for stimulation and not in response to
HeLa-II cells transduced with responder HLA-DPB1
molecules or HLA-DPB1 negative HeLa-II cells
(Figure 4). Some CD41 T cell lines showed minor
IFN-g release in response to HeLa-II cells transduced
with responder HLA-DPB1 molecules and HLA-DP
negative HeLa-II cells, which may be explained by
non-HLA-DP restricted recognition of HeLa-II cells.
As shown in Figure 4, CD41 T cells were also
stimulated with HeLa-II cells transduced with the
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Figure 3. Comparable HLA-DPB1-specific immune response generated against HLA-DPB1 molecules classified in 4 different groups. (A) Purified
CD41 T cells derived from a healthy HLA-DPB1*0301 typed individual were stimulated with HeLa-II cells transduced with HLA-DPB1*1701, *1401,
*0201, or *0401. At day 14, 25,000 CD41 T cells from each cell line were restimulated with 50,000 HLA-DPB1-transduced HeLa-II cells used for stim-
ulation (-) or HeLa-II cells transduced with control responder HLA-DPB1*0301 molecules (,). IFN-g release (pg/mL) measured in 50 mL supernatant
upon restimulation is shown. (B) IFN-g production of the 4 different HLA-DPB1-specific CD41 T cell lines in response to HLA-DPB1-transduced HeLa-
II cells used for stimulation is shown using different numbers of responder cells. IFN-g release was determined in 50-mL supernatant following overnight
incubation using 25,000, 10,000, or 2000 responder cells. Immune responses generated against different HLA-DPB1 molecules are depicted using
different symbols and lines. (C) Recognition of 2 representative HLA-DPB1*1401-specific CD41 T cell clones in response to HeLa cells transduced
with HLA-DPB1*1401 combined with different HLA-DPA1 molecules. Specificity for HLA-DPB1*14 of the CD41 T cell clones is shown by recognition
of responder EBV-LCL transduced with HLA-DPB1*14. IFN-g production in 50-mL supernatant was determined by ELISA.
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production observed in response to HeLa-II cells
transduced with the autologous HLA-DPB1 molecule
illustrated that CD41 T cell responses could also be
generated against polymorphicminor histocompatibil-
ity antigens [30,31] or cell type-specific peptides
presented in ‘‘self’’-HLA-DP.
These data demonstrate that HLA-DPB1-specific
CD41T cell responses can result from all HLA-DPB1
mismatch combinations.Crossrecognition of HLA-DPB1 Molecules by
HLA-DPB1-Specific CD41 T Cells
To investigate whether we could identify
additional patterns in crossreactivity of HLA-DPB1
molecules by HLA-DPB1-specific CD41 T cells, all
HLA-DPB1-specific CD41 T cell lines shown inFigure 4 were analyzed for crossrecognition of 12 dif-
ferent HLA-DPB1 molecules. Complete data sets of
experiments from 2 representative responders are
shown in Figure 5. In Figure 5A, crossrecognition of
different HLA-DPB1 molecules by 12 HLA-DPB1-
specific CD41 T cell lines generated from an HLA-
DPB1*0301 typed responder (group 2) [21] is shown,
and in Figure 5B data from anHLA-DPB1*0401 typed
responder (group 4) [21] are shown.
Abroaddiversity in crossreactivitybetweendifferent
HLA-DPB1-specific CD41 T cell lines was observed
(Figure 5). CD41 T cell lines with the same HLA-
DPB1 specificity generated from different responders
showed crossrecognition of different HLA-DPB1 mol-
ecules. This phenomenon is likely to be caused by a dif-
ferent TCR-repertoire present in each responder.
In total, 33 of 42HLA-DPB1-specificCD41Tcell
lines showed crossrecognition of at least 1 other
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Figure 4. HLA-DPB1-specific immune responses can be generated from all HLA-DPB1 mismatch combinations. Purified CD41 T cells derived from 4
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cognition of the different HLA-DPB1-specific CD41
Tcell lines was observed.However, consistent patterns
in crossrecognition reported in previous studies were
observed. All HLA-DPB1*09-specific CD41 T cell
lines (n5 4) recognizedHLA-DPB1*17 and vice versa.
Furthermore, allHLA-DPB1*03-specificCD41Tcell
lines (n 5 3), generated from responders who did not
express HLA-DPB1*03, showed crossrecognition
with HLA-DPB1*14 and vice versa. Finally, HLA-
DPB1*0401 and HLA-DPB1*0402-specific CD41 T
cell lines generated from HLA-DPB1*0201 or HLA-
DPB1*0301 typed responders (n 5 2) showed cross-
reactivity with each other. These crossrecognized
HLA-DPB1 molecules were previously classified in
different groups [19,21]. Furthermore, we did not
find additional patterns in crossrecognition. These
data showed that the previously reported
classification ofHLA-DPB1molecules in different im-
munogenicity groups was predictive for crossrecogni-
tion by HLA-DPB1-specific CD41 T cells.DISCUSSION
In this study, we showed that all HLA-DPB1 mis-
match combinations as defined by allele typing resulted
in high-frequency polyclonal immune responses.As reported previously, crossrecognition of different
HLA-DPB1 molecules by HLA-DPB1-specific CD41
T cell clones was a common observation. However, we
demonstrated that frequently observed crossreactivity
between specific HLA-DPB1 molecules did not pre-
clude the capacity to generate HLA-DPB1 responses
between individuals expressing theseHLA-DPB1mole-
cules. These data illustrate that an algorithm defining
permissive and non-permissive mismatches for HLA-
DPB1 allo-reactivity cannot be developed merely based
on T cell recognition patterns.
We demonstrated that a single stimulation with
a cell population expressing HLA-DP molecules in
combination with relevant molecules involved in the
HLA-class-II processing pathway resulted in high-
frequency of HLA-DPB1-specific CD41 T cells in
.95% of the different stimulator/responder combina-
tions analyzed. Responder cells expressed 1 of the 4
most common HLA-DPB1 molecules present in
a northern European population [23] and 97% of
SCT donors in our center expressed at least 1 of
these HLA-DPB1 molecules. HLA-DPB1 molecules
used for stimulation comprised 76% to 99% of
HLA-DPB1 molecules present in different ethnic
populations [23]. We demonstrated that all HLA-
DPB1 mismatches as defined by allele typing were
immunogenic.
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Figure 5. Crossrecognition of 12 different HLA-DPB1 molecules by HLA-DPB1-specific CD41 T cells. Twelve CD41 T cell lines specific for 12 dif-
ferent HLA-DPB1 alleles were tested for recognition of HeLa-II cells transduced with 12 different HLA-DPB1molecules. Each row in 1 figure represents
recognition of the 12 different HLA-DPB1 molecules by 1 CD41 T cell line. Gray boxes represent recognition of the specific HLA-DPB1 molecule used
for stimulation for each CD41 T cell line. ‘‘11’’ indicates more than 100 pg/mL IFN-g production in 50-mL supernatant by 10,000 CD41 T cells upon
restimulation with a specific HLA-DPB1 transduced HeLa-II cell line. ‘‘1’’ indicates more than 100 pg/mL IFN-g production in 50-mL supernatant by
25,000 CD41 T cells upon restimulation with a specific HLA-DPB1-transduced HeLa-II cell line. (A) Results of 12 different HLA-DPB1-specific
CD41 T cell lines generated from an HLA-DPB1*0301 typed responder. (B) Results of 12 different HLA-DPB1-specific CD41 T cell lines generated
from an HLA-DPB1*0401 typed responder.
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in crossrecognition of HLA-DPB1 molecules
[19,27,32], illustrating that the proposed classification
of HLA-DPB1 molecules in different immunogenicity
groups [19,21] was predictive for crossrecognition.
The high degree in similarity of amino acid
sequences in the hypervariable region of HLA-DPB1
molecules classified within group 1 (HLA-DPB1*09
and HLA-DPB1*17) and group 2 (HLA-DPB1*03
and HLA-DPB1*14) is likely to explain the frequently
observed crossreactivity between HLA-DPB1 mole-
cules classified within these groups. In addition, we
demonstrated a broad diversity of crossrecognition
patterns by several other HLA-DPB1-specific CD41
T cell lines. We demonstrated that allo-HLA-DPB1-
specific immune responses comprised a variety of T
cell clones apparently generated against different im-
munogenic epitopes. Crossrecognition patterns of
these T cell clones could often not simply be explained
by the presence or absence of specific shared amino acidsequences in the hypervariable region of HLA-DPB1
(data not shown), illustrating the complexity of the
3-dimensional structure of an HLA-DP-peptide
complex for T cell recognition.
In this study, we demonstrated a redundancy of epi-
topes against which allo-reactive T cells can be gener-
ated. Not only differences in the HLA-DPB1 molecule
but also the HLA-DPA1 molecule contributed to the
specificity of allo-HLA-DP responses. Furthermore,
previous reports have shown that substitutions of
single amino acids in the HLA-DPB1 molecule
influenced T cell recognition either by direct contact
with the TCR or indirectly by changing the conforma-
tion of peptides presented in the groove [33]. We
demonstrated by generating immune responses
against HeLa-II cells transduced with ‘‘self’’-HLA-DP
molecules that polymorphic peptides presented in
‘‘self’’-HLA-DP were also capable of stimulating allo-
responses. Although the magnitude of these immune
responses was lower than allo-HLA-DP responses, it is
Biol Blood Marrow Transplant 16:1282-1292, 2010 1291Immunogenicity of HLA-DPB1known from HLA-matched donor recipient pairs that
allo-immune responses directed against mHags pre-
sented inHLA-class-I orHLA-class-II are capable of in-
ducing clinically significant allo-responses [34-37]. In
conclusion, although individuals expressing highly
similar HLA-DPB1 molecules may clonally delete T
cells specific for shared epitopes, our data demonstrate
that sufficient differences between the HLA-DP mole-
cules remain to mount strong allo-HLA-DP-specific
immune responses.
Although we demonstrated immunogenicity of all
HLA-DPB1mismatches, clinical studies showed a sig-
nificant decrease in overall survival (OS) and higher
risk for TRM for specific HLA-DPB1 mismatches
[18,21,38]. However, the studies also showed that
these specific mismatches enhanced neither GVHD
nor GVL reactivity. Because both the risk of disease
relapse and the risk of aGVHD did not significantly
differ, the observed effect on OS may have resulted
from mechanisms other than merely differences in
allo-reactivity between the HLA-DPB1 molecules.
Specific HLA-DPB1 molecules have been associated
with an increased susceptibility to particular diseases
[39-41]. The observed adverse effect on OS of some
HLA-DPB1 mismatches may therefore be the result
of indirect (immunologic) factors. For example, the
presence of single nucleotide polymorphisms within
the innate immunity receptor NOD2/CARD15 be-
tween recipient and donor has been associated with
a significant reduction in OS [42-44]. Although the
exact mechanisms by which these data can be
explained are not yet resolved, the observed effects
are likely to be caused by indirect influences on the
immune system as well.
In conclusion, we show that all HLA-DPB1 mis-
matches as defined by allele typing resulted in high-
frequency CD41 T cell responses. Furthermore, we
show that crossrecognition of HLA-DPB1 molecules
is a broadly observed phenomenon and confirm
previously described patterns in crossreactivity. We
demonstrate that frequently observed crossreactivity
between specific HLA-DPB1 molecules did not pre-
clude allo-HLA-DPB1 responses between individuals
expressing these HLA-DPB1 molecules. Together,
these data demonstrate that a high degree in similar-
ity between HLA-DPB1 alleles is predictive for
crossreactivity, but not for immunogenicity, and
illustrate that T cell recognition patterns may not
predict alloreactivity.ACKNOWLEDGMENTS
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